Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Short-term treatment with taurolidine is associated with liver injury

Fig. 3

Liver biochips were perfused with taurolidine at a concentration of 100 μg/ml and revealed no significant hepatocyte damage assessed by measurement of liver enzymes in biochip supernatants. Whereas a concentration of 1 mg/ml taurolidine revealed significantly increased levels of ASAT and GLDH (a, b). IL-6 levels showed similar results, with a significant increase after high-dose treatment (c). Serum levels of TNF-α, IL-1ß and IL-10 were not significantly different between controls and taurolidine with 1 mg/ml (d). Representative data of three independent experiments are shown

Back to article page